In the Asia & Oceania region, this product was launched  in South Korea in October 2013. Additional indication applications were submitted in the  U.S. in March 2014 and in Europe the following month for  the treatment of men with metastatic castration-resistant  prostate cancer who have not received chemotherapy. Enzalutamide is a once-daily oral androgen receptor  signaling inhibitor, which is being developed jointly with  Medivation, Inc. (“Medivation”). In the U.S., Astellas and  Medivation co-promote XTANDI and share costs and   profits equally. In all countries excluding the U.S., Astellas  will develop and sell XTANDI, while paying Medivation   royalties based on sales. * The following precaution has been issued regarding indication: the efficacy and  safety of the drug have not been established in patients with prostate cancer  who have not received chemotherapy. One of the features of Astellas is the large number of dis- tinctive products offered in each region, in addition to the  global products mentioned above. Growth in sales of these  products also contributes to consolidated sales. Sales of drugs in the Micardis product line, including  Micombi and Micamlo, increased by 8.9%, to ¥97.6 billion.  Sales continued to grow favorably for Micamlo, a combina- tion drug with a calcium antagonist. In fiscal 2013, the  market for angiotensin II receptor blockers (ARB) in Japan  expanded 3.2%, to around ¥610.0 billion. Steady expan- sion in sales of the Micardis line of drugs contributed to its  current ARB market share of around 18% (on a value  basis). Furthermore in May 2013, “Micamlo Combination  Tablets BP” was newly launched. In Japan, Astellas is co-promoting the Micardis product line with Nippon  Boehringer Ingelheim Co., Ltd. Sales of Symbicort, which is a combination drug of an  inhaled corticosteroid and a rapid and long-acting beta-2  agonist, registered favorable growth of 28.5%, to ¥35.6  billion. Additional approval for this drug was obtained in  June 2012 for new dosage and administration on an as- needed basis for reliever therapy in addition to maintenance  therapy for adult bronchial asthma. Approval for Symbicort  was also acquired in August 2012 for the additional indica- tion of chronic obstructive pulmonary disease. Symbicort’s  sales in fiscal 2013 expanded significantly thanks to these  additional indications along with growth in the combination  drug market. The market in Japan for adult inhaled steroid  treatment including combination drugs grew 12.5% year on  year to approximately ¥105.0 billion in fiscal 2013. Symbicort  also steadily grew its share of this market to around 37%  (on a value basis). The dissemination of guidelines on con- trolling and preventing asthma and activities to raise public  awareness of this condition has contributed to annual  growth of the market for combination drugs. Astellas will  continue co-promoting Symbicort with AstraZeneca K.K.  in Japan to achieve further market penetration. Sales of Celecox increased 18.4%, to ¥44.3 billion. This  product has shown steady sales growth, following the  acquisition of approvals for additional indications of lum- bago and acute pain on top of the indications of rheuma- toid arthritis and osteoarthritis. We further strengthened the  reputation of Celecox as an anti-inflammatory that causes  minimal gastrointestinal tract disturbance, capitalizing on  the revision of prescribing information to reflect the results  of post-marketing clinical trials, along with the “Clinical  Guidelines for the Management of Low Back Pain,” issued  in October 2012 by the Japanese Orthopaedic Association.  In fiscal 2013, the market for anti-inflammatory agents in  Japan was worth approximately ¥88.0 billion, up 3.8%  from the previous fiscal year. The market share of Celecox  grew steadily to around 55% (on a value basis). Astellas  will continue co-promoting this drug with Pfizer Japan  Inc. while targeting an even higher share of the oral  anti-inflammatory market. Symbicort (Treatment for adult bronchial asthma and chronic obstructive pulmonary disease) Sales of Mainstay Products by Geographical Area Micardis (Hypertension treatment) Micombi (Combination drug with a diuretic) Micamlo (Combination drug with a long-acting calcium antagonist) Japan Astellas Pharma Inc.  _ Annual Report 2014 90 Celecox (Anti-inflammatory agent (Selective COX-2 inhibitor))